Search research articles
Contact Us
Filters
Showing results (271-280 of 437) with videos related to
Page
of 44
Sort By:
Molecular Cancer Therapeutics
|
January 27, 2016
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Aysegül Ilhan-Mutlu, Matthias Osswald, Yunxiang Liao, et al.
JTO Clinical and Research Reports
|
November 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC
Makoto Nishio, Takashi Seto, Martin Reck, et al.
Cold Spring Harbor Molecular Case Studies
|
November 23, 2019
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1-ALK</i>-rearranged lung cancer
Steffen Dietz, Petros Christopoulos, Lisa Gu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
Antonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.
Future Oncology (London, England)
|
April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancer
Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 13, 2012
Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2019
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2025
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults
Michael Abele, Anton Karelin, Michaela Pogoda, et al.
The Lancet. Oncology
|
February 21, 2012
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Page
of 44
Search research articles
Search
Showing results (271-280 of 437) with videos related to
Sort By:
Page
of 44
Molecular Cancer Therapeutics
|
January 27, 2016
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Aysegül Ilhan-Mutlu, Matthias Osswald, Yunxiang Liao, et al.
JTO Clinical and Research Reports
|
November 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC
Makoto Nishio, Takashi Seto, Martin Reck, et al.
Cold Spring Harbor Molecular Case Studies
|
November 23, 2019
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1-ALK</i>-rearranged lung cancer
Steffen Dietz, Petros Christopoulos, Lisa Gu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
Antonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.
Future Oncology (London, England)
|
April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancer
Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 13, 2012
Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2019
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2025
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults
Michael Abele, Anton Karelin, Michaela Pogoda, et al.
The Lancet. Oncology
|
February 21, 2012
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Page
of 44